These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32978063)

  • 1. In Vitro Tailoring of Regulatory T Cells Prior to Cell Therapy.
    Baeten P; Hellings N; Broux B
    Trends Mol Med; 2020 Nov; 26(11):1059-1060. PubMed ID: 32978063
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunotherapy Deriving from CAR-T Cell Treatment in Autoimmune Diseases.
    Chen Y; Sun J; Liu H; Yin G; Xie Q
    J Immunol Res; 2019; 2019():5727516. PubMed ID: 32083141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic potential of CRISPR/Cas9 gene editing in engineered T-cell therapy.
    Gao Q; Dong X; Xu Q; Zhu L; Wang F; Hou Y; Chao CC
    Cancer Med; 2019 Aug; 8(9):4254-4264. PubMed ID: 31199589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory T cell therapy: Current and future design perspectives.
    Rana J; Biswas M
    Cell Immunol; 2020 Oct; 356():104193. PubMed ID: 32823038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
    Morgan MA; Büning H; Sauer M; Schambach A
    Front Immunol; 2020; 11():1965. PubMed ID: 32903482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applications of CRISPR Genome Editing to Advance the Next Generation of Adoptive Cell Therapies for Cancer.
    Fix SM; Jazaeri AA; Hwu P
    Cancer Discov; 2021 Mar; 11(3):560-574. PubMed ID: 33563662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR/Cas systems to overcome challenges in developing the next generation of T cells for cancer therapy.
    Huang D; Miller M; Ashok B; Jain S; Peppas NA
    Adv Drug Deliv Rev; 2020; 158():17-35. PubMed ID: 32707148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory Considerations for Genome-Edited T-cell Therapies.
    Jadlowsky JK; Chang JF; Spencer DH; Warrington JM; Levine BL; June CH; Fraietta JA; Singh N
    Cancer Immunol Res; 2024 Sep; 12(9):1132-1135. PubMed ID: 39018097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Off-the-shelf CAR-T cells could prove paradigm shifting for autoimmune diseases.
    Baker DJ; June CH
    Cell; 2024 Sep; 187(18):4826-4828. PubMed ID: 39241743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance.
    Zhang Q; Lu W; Liang CL; Chen Y; Liu H; Qiu F; Dai Z
    Front Immunol; 2018; 9():2359. PubMed ID: 30369931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empowering chimeric antigen receptor T-cell therapy with CRISPR.
    Zhou X
    Biotechniques; 2020 Apr; 68(4):169-171. PubMed ID: 31973565
    [No Abstract]   [Full Text] [Related]  

  • 12. Strategies to cure experimental autoimmune colitis using antigen-specific Foxp3+ regulatory T cells.
    de Zoeten EF; Hancock WW
    Gastroenterology; 2008 Jun; 134(7):2171-4. PubMed ID: 18482583
    [No Abstract]   [Full Text] [Related]  

  • 13. Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing.
    Liu J; Zhou G; Zhang L; Zhao Q
    Front Immunol; 2019; 10():456. PubMed ID: 30941126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. International Regensburg Center for Interventional Immunology (RCI) symposium on "Synthetic immunology and environment-adapted redirection of T cells", 17-18 July, 2019, Regensburg, Germany.
    Beckhove P; Edinger M; Feuerer M; Gattinoni L; Abken H
    Cancer Immunol Immunother; 2020 Apr; 69(4):677-682. PubMed ID: 32123937
    [No Abstract]   [Full Text] [Related]  

  • 15. Regulating the regulators: Is introduction of an antigen-specific approach in regulatory T cells the next step to treat autoimmunity?
    Janssens I; Cools N
    Cell Immunol; 2020 Dec; 358():104236. PubMed ID: 33137651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Future of CAR T Therapeutics to Treat Autoimmune Disorders.
    Pecher AC; Hensen L; Lengerke C; Henes J
    Mol Diagn Ther; 2024 Sep; 28(5):593-600. PubMed ID: 39078456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric antigen receptor-engineered regulatory T lymphocytes: promise for immunotherapy of autoimmune disease.
    Yi L; Weifan Y; Huan Y
    Cytotherapy; 2019 Sep; 21(9):925-934. PubMed ID: 31105041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caribou's first CRISPR CAR-T impresses.
    Nat Biotechnol; 2022 Jun; 40(6):807. PubMed ID: 35705709
    [No Abstract]   [Full Text] [Related]  

  • 19. The Biology of T Regulatory Type 1 Cells and Their Therapeutic Application in Immune-Mediated Diseases.
    Roncarolo MG; Gregori S; Bacchetta R; Battaglia M; Gagliani N
    Immunity; 2018 Dec; 49(6):1004-1019. PubMed ID: 30566879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
    Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
    Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.